Disclaimer

This Web site has been created solely for the purpose of providing information about services available from Richmond Pharmacology (RP). The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.

Due to web security any ideas and or information sent to RP via this Web site will be deemed not to be confidential and by sending information, you are granting RP unrestricted and irrevocable licence to use, reproduce, display, perform, modify, transmit and distribute. However RP will not release your name or otherwise publicise the fact that information was sent unless RP obtains your permission to do so or if RP is required to do so by law.

Please note that RP does not endorse any other Web sites accessed via this site or accepts any responsibility for the content or accuracy of information contained on that site. In no event will RP be liable to any party for any damages arising from any use of or access to this Web site.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event